Evidence Snapshot

Gonadotropin-releasing hormone receptor

CHEMBL1855 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:17:30Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:17 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1855

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gonadotropin-releasing hormone receptor as ChEMBL target CHEMBL1855, mapped to UniProt P30968. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Gonadotropin-releasing hormone receptor

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1855

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P30968

Gonadotropin-releasing hormone receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Gonadotropin-releasing hormone receptor matters

As of 2026-09-13

Gonadotropin-releasing hormone receptor is reviewed as Gonadotropin-releasing hormone receptor (UniProt P30968); Gonadotropin-releasing hormone receptor shows approved-linked disease relevance led by endometriosis. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded.; the current evidence base includes 16 approved drugs, 1768 compounds, and 301 assays, with lead potency reaching pChEMBL 10.2.

Protein context

Gonadotropin-releasing hormone receptor

Gonadotropin-releasing hormone receptor Sequence length is 328 aa.

Review this target as Gonadotropin-releasing hormone receptor, mapped to UniProt P30968. Sequence length is 328 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P30968 Protein

Disease context

endometriosis

Gonadotropin-releasing hormone receptor shows approved-linked disease relevance led by endometriosis. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ELAGOLIX, ELAGOLIX SODIUM, LEUPROLIDE ACETATE.

Start review with endometriosis because it currently carries approved-linked support. Linked drugs include ELAGOLIX, ELAGOLIX SODIUM, LEUPROLIDE ACETATE, LINZAGOLIX. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 9 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 1768 compounds, and 301 assays for this target. The dominant activity type is IC50. CHEMBL22055 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL22055 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine

16 approved pChEMBL 10.2

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Gonadotropin-releasing hormone receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30968, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why endometriosis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1768

Total Compounds

301

Total Assays

Approved Drugs

IC50: 2131.0, KI: 880.0, KD: 47.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL22055	10.2	IC50	Clinical
No preferred name CHEMBL379629	10.2	IC50	—
No preferred name CHEMBL435167	10.2	IC50	—
No preferred name CHEMBL210294	10.2	IC50	—
No preferred name CHEMBL377396	10.2	IC50	—

Approved Drugs

Structure	Compound	First Approval
	LINZAGOLIX CHEMBL3668014	2022
	RELUGOLIX CHEMBL1800159	2019
	ELAGOLIX SODIUM CHEMBL502182	2018
	DEGARELIX CHEMBL415606	2008
	ABARELIX CHEMBL1252	2003
	CETRORELIX CHEMBL1200490	1999
	GANIRELIX ACETATE CHEMBL5314377	1999
	LEUPROLIDE CHEMBL1201199	1985
	GONADORELIN CHEMBL1007	1982

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:17:30Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:17 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1855